MedTrace Logo

The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis

NCT01532284 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2018-01-16

No results posted yet for this study

Summary

A pragmatic, multicentre, randomized double-blind controlled trial with an intention-to-treat analysis, of the use of preimplantation genetic screening (PGS) for aneuploidy by means of microarray comparative genomic hybridization (CGH) for the chromosomal analysis of the polar bodies (PB) of oocytes collected after ovarian stimulation for in vitro fertilization (IVF), and with the intention to assess the genetic competence of oocytes of advanced biological age, and the effect of this technique on reproductive outcome.

Conditions

  • Aneuploid Oocytes

Interventions

OTHER

Polar Body Biopsy

PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.

Sponsors & Collaborators

  • European Society of Human Reproduction and Embryology

    lead OTHER

Principal Investigators

  • Karen Sermon, Prof. dr. · ESHRE

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
36 Years
Max Age
41 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2016-12-31
Completion
2017-09-30

Countries

  • Belgium
  • Germany
  • Greece
  • Israel
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01532284 on ClinicalTrials.gov